MDGL - Company ID 0001157601
The table below shows MADRIGAL PHARMACEUTICALS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | - | $6.23M | $0.00 | $0.00 | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $813.83M |
MADRIGAL PHARMACEUTICALS, INC. reported annual revenue of $958.40M for fiscal year 2025. That is up 432.1% from $180.13M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $147.00K (FY 2012) to $958.40M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $435.06M |
| $108.15M |
| $48.13M |
| $37.32M |
| $21.86M |
| Operating income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M | -$206.67M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$288.28M | -$465.89M | -$373.63M | -$295.25M | -$241.85M | -$202.24M |
| EPS (diluted) | -$10.15 | -$17.31 | -$17.33 | -$17.23 | -$14.63 | -$13.09 |